FrancophonIA/ELRC3.0 huggingface dataset:
English: Docetaxel blocks the ability of cancer cells to destroy the internal ‘skeleton' that allows them to divide and multiply.
Maltese: Docetaxel jimblokka l-kapaċità taċ-ċelloli tal-kanċer li jkissru l‘iskeletru' intern li jippermettilhom li jinqasmu u jimmultiplikaw.
English: The CHMP therefore concluded that the benefits of Docetaxel Teva Generics outweigh its risks and recommended that the marketing authorisation be granted in the Netherlands and the concerned Member States.
Maltese: Is-CHMP għalhekk ikkonkluda li l-benefiċċji ta' Docetaxel Teva Generics jisbqu r-riskji tiegħu u rrakkomanda li jingħata awtorizzazzjoni għat-tqegħid fis-suq fil-Pajjiżi l-Baxxi u fl-Istati Membri kkonċernati.
English: Questions and answers on Docetaxel Teva Generics (docetaxel, 20 mg and 80 mg powder and solvent for solution for infusion)
Maltese: Hija tiġi bħala trab u solvent sabiex jiġu magħmulin f'soluzzjoni għal infużjoni (dripp ġo vina).
English: 3 September 2012
Maltese: 3 ta' Settembru 2012
English: Medicines containing trimetazidine have been available since the 1970s and are currently marketed in Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Slovenia and Spain.
Maltese: Il-mediċini li fihom it-trimetażidina ilhom fis-suq sa mis-snin sebgħin, u bħalissa jinstabu fis-swieq talBulgarija, Ċipru, ir-Repubblika Ċeka, id-Danimarka, l-Estonja, Franza, il-Ġermanja, il-Greċja, lUngerija, l-Irlanda, l-Italja, il-Latvja, il-Litwanja, il-Lussemburgu, Malta, il-Polonja, il-Portugall, irRumanija, is-Slovakkja, is-Slovenja u Spanja.
English: Outcome of a procedure under Article 31 of Directive 2001/83/EC as amended
Maltese: Eżitu ta' proċedura skont l-Artikolu 31 tad-Direttiva 2001/83/KE kif emendat
English: What is trimetazidine?
Maltese: X'inhi t-trimetażidina?
English: Questions and answers on the review of medicines containing trimetazidine (20 mg tablets, 35 mg modified release tablet and 20 mg/ml oral solution)
Maltese: Mistoqsijiet u tweġibiet dwar ir-reviżjoni tal-mediċini li fihom it-trimetażidina (20 mg pilloli, 35 mg pillola b'rilaxx modifikat u 20 mg/ml soluzzjoni orali)
English: Which data has the CHMP reviewed?
Maltese: Liema dejta ġiet riveduta mis-CHMP?
English: The CHMP looked at data from clinical studies, the published literature, spontaneous reports of side effects and data submitted by the companies that market medicines containing trimetazidine.
Maltese: Is-CHMP stħarreġ id-dejta minn studji kliniċi, it-tagħrif ippubblikat, rapporti spontanji dwar effetti sekondarji u dejta ppreżentata mill-kumpaniji li jqiegħdu fis-suq mediċini li fihom it-trimetażidina.
English: In addition, there were concerns regarding the safety of trimetazidine-containing medicines following reports of Parkinson syndrome (a group of symptoms that include shaking, slow movement and muscle stiffness) and other motor disorders such as tremor (shaking), muscle rigidity and walking disorders, and restless legs syndrome (a disorder where the patient has uncontrollable urges to move the limbs to stop uncomfortable, painful or odd sensations in the body, usually at night).
Maltese: Barra dan, qam tħassib dwar is-sigurtà ta' mediċini li fihom it-trimetażidina wara rapporti tas-sindrome ta' Parkinson (grupp ta' sintomi li jinkludu rogħda, moviment bil-mod u għebusija fil-muskoli) u disturbi motorji oħrajn bħal tregħid (rogħda), muskoli riġidi u disturbi fil-mixi, u s-sindrome tar-riġlejn irrikwieti (disturb li fih il-pazjent ikollu bżonn inkontrollabli li jċaqlaq riġlejh biex iwaqqaf sensazzjonijiet skomdi, strambi u ta' uġigħ fil-ġisem, ġeneralment filgħaxija).
English: • Trimetazidine should be discontinued permanently in patients who develop movement disorders such as parkinsonian symptoms.
Maltese: • L-użu tat-trimetażidina għandu jitwaqqaf b'mod permanenti f'pazjenti li jiżviluppawlhom disturbi fil-moviment bħal sintomi ta' Parkinson.
English: Regarding the use of trimetazidine in tinnitus, vertigo and visual field disturbances, the studies had poor methodology and did not demonstrate a clinical benefit of trimetazidine when compared with placebo (a dummy treatment) or alternative medicines.
Maltese: Rigward l-użu tat-trimetażidina fil-kura tal-akufeni, sturdamenti u disturbi fil-kamp tal-vista, l-istudji li saru ma kellhomx metodoloġija adegwata u ma urew l-ebda benefiċċju kliniku tat-trimetażidina apparagun mal-użu tal-plaċebo (trattament finta) jew ta' mediċini alternattivi.
English: Trimetazidine is also used to treat the symptoms of vertigo (a spinning sensation) and tinnitus (ringing sensation in the ears), and to treat reduced vision and visual field disturbances (unclear or disturbed vision) due to problems affecting the blood vessels.
Maltese: It-trimetażidina tintuża wkoll biex tikkura s-sintomi ta' sturdament (mejt) u l-akufeni (sensazzjoni ta' tisfir fil-widnejn), u biex jittratta tnaqqis fil-vista u disturbi fil-kamp tal-vista (vista mhux ċara jew disturbata) kkaġunati minn problemi li jaffettwaw il-vini tad-demm.
English: • Trimetazidine should only be used in the symptomatic treatment of angina pectoris, and only as add-on to existing treatments in patients who are not adequately controlled by or who are intolerant to other medicines for angina pectoris.
Maltese: • It-trimetażidina għandha tintuża biss fil-kura sintomatika tal-anġina pektoris, u biss bħala żieda ma' trattamenti diġà eżistenti f'pazjenti li ma jkunux ikkontrollati tajjeb jew li jkunu intolleranti għal mediċini oħrajn li jintużaw kontra l-anġina pektoris.
English: These symptoms were seen in some patients with no previous history of Parkinson syndrome, and in many cases their symptoms resolved when they stopped taking trimetazidine.
Maltese: Dawn is-sintomi dehru f'pazjenti li ma kellhom lebda storja preċedenti tas-sindrome ta' Parkinson, u f'ħafna każi dawn is-sintomi li kienu qed iġarrbu għebu malli waqfu jieħdu t-trimetażidina.
English: In April 2011, the French medicines regulatory agency concluded that, based on a review of the evidence in France, the risks of medicines containing trimetazidine were greater than the benefits for all the authorised indications.
Maltese: F'April 2011 l-Aġenzija regolatorja Franċiża għall-mediċini waslet għall-konklużjoni li, abbażi ta' analiżi tal-provi li saret fi Franza, ir-riskji tal-mediċini li fihom it-trimetażidina kienu ikbar mill-benefiċċji għallindikazzjonijiet awtorizzati kollha.
English: An analysis of relevant safety data showed that movement disorders, including Parkinsonism, cannot be excluded with trimetazidine, although these are not common and are reversible after discontinuing trimetazidine.
Maltese: Analiżi tad-dejta relevanti dwar is-sigurtà uriet li disturbi fil-moviment, inklużi s-sintomi ta' Parkinson, ma jistgħux jiġu esklużi bit-trimetażidina, għad illi dawn mhumiex komuni u huma riversibbli wara li jitwaqqaf l-użu tat-tat-trimetażidina.
English: In addition, the Committee recommended new contraindications and warnings to reduce and manage the possible risk of movement disorders, associated with the use of this medicine.
Maltese: Barra dan, il-Kumitat irrakkomanda kontraindikazzjonijiet u twissijiet ġodda ħalli jiġi mnaqqas u kkontrollat ir-riskju possibbli ta' disturbi fil-moviment li huwa assoċjat mal-użu ta' din ilmediċina.
English: Trimetazidine is a ‘metabolic agent', a medicine which has an effect on metabolism (the process by which substances are broken down in the body).
Maltese: It-trimetażidina hija ‘aġent metaboliku', jiġifieri mediċina li għandha effett fuq il-metaboliżmu (ilproċess li bih is-sustanzi jitkissru fil-ġisem).
English: The European Commission issued a decision on this opinion on 3 September 2012.
Maltese: Il-Kummissjoni Ewropea ħarġet deċiżjoni dwar din l-opinjoni fit-3 ta' Settembru 2012.
English: • Prescribers should no longer prescribe trimetazidine for treating tinnitus, vertigo and disturbances in vision and switch patients to appropriate alternative treatment.
Maltese: • Dawk li jiktbu r-riċetti ma għandhomx jibqgħu jagħtu t-trimetażidina biex jikkuraw l-akufeni, listurdamenti u d-disturbi fil-kamp tal-vista, u għandhom jagħtu lill-pazjenti kura alternattiva xierqa.
English: Based on the evaluation of the currently available data and the scientific discussion within the Committee, the CHMP concluded that the benefits of trimetazidine continue to outweigh its risks when used as add-on treatment in patients with angina pectoris, but that changes should be made to the product information to ensure the safe use of these medicines.
Maltese: Abbażi tal-valutazzjoni tad-dejta disponibbli bħalissa u tad-diskussjoni xjentifika li saret fil-Kumitat, isCHMP wasal għall-konklużjoni li l-benefiċċji tat-trimetażidina għadhom jegħlbu lir-riskji tiegħu meta din tintuża bħala kura supplimentari fuq pazjenti b'anġina pektoris.
English: • severe dyskinesia.
Maltese: • diskinesija gravi.
English: EMA/388409/2014 EMEA/H/C/00132
Maltese: EMEA/H/C/00132
English: The full EPAR for Tasmar can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is available as tablets (100 mg and 200 mg).
Maltese: Jiġi bħala pilloli (100 mg u 200 mg).
English: • phaeochromocytoma (a tumour of the adrenal gland);
Maltese: • feokromoċitoma (‘phaeochromocytoma', tumur tal-glandola adrenali [adrenal gland]);
English: In the switch study, more patients responded to Tasmar (53%; 40 out of 75) than to entacapone (43%; 32 out of 75).
Maltese: Fl-istudju tal-qlib, iktar pazjenti rrispondew għal Tasmar (53%, 40 minn 75) milli għal entacapone (43%, 32 minn 75).
English: Tasmar is a medicine that contains the active substance tolcapone.
Maltese: Tasmar huwa mediċina li fiha s-sustanza attiva tolkapon.
English: This summary was last updated in 06-2014.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'06-2014.
English: Tasmar was originally studied in a total of 594 patients, in two 13-week studies and one six-week study.
Maltese: Oriġinarjament Tasmar ġie studjat f'total ta' 594 pazjent, f'żewġ studji ta' 13-il ġimgħa u studju wieħed ta' sitt ġimgħat.
English: This is a summary of the European public assessment report (EPAR) for Tasmar.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Tasmar.
English: • a history of neuroleptic malignant syndrome (a dangerous nervous disorder usually caused by antipsychotic medicines), rhabdomyolysis (breakdown of muscle fibres) or hyperthermia (heat stroke);
Maltese: • storja ta' sindromu malinn newrolettiku (disturb perikoluż tan-nervituri normalment ikkawżat minn medicini antipsikotici), rabdomjoliżi (‘rhabdomyolysis', it-tkissir tal-fibri muskolari) jew ipertermija (żieda tat-temperatura tal-ġisem);
English: There was a reduction of about 20 to 30% in ‘off' time in patients taking Tasmar.
Maltese: Ġie rreġistrat tnaqqis ta' madwar 20 sa 30% fiż-żmien ‘off' fil-pazjenti li ħadu Tasmar.
English: The most common side effects with Tasmar (seen in more than 1 patient in 10) are nausea (feeling sick), loss of appetite, diarrhoea, dyskinesia (uncontrollable movements), dystonia (muscle spasms), headache, dizziness, sleep disorders, excessive dreaming, somnolence (sleepiness), confusion, hallucination (seeing things that are not there) and orthostatic complaints (dizziness on standing).
Maltese: L-effetti sekondarji l-aktar komuni b'Tasmar (li dehru f'iktar minn pazjent 1 minn 10) huma nawżja (dardir), telf tal-aptit, dijarrea, diskinesija (movimenti inkontrollabbli), distonija (spasmi fil-muskoli), uġigħ ta' ras, sturdament, disturbi fl-irqad, ħolm eċċessiv, ħedla tan-ngħas, konfużjoni, alluċinazzjonijiet (dehra ta' affarijiet li jkunu immaġinarji) u sturdament ortostatiku (li jseħħ meta wieħed iqum bilwieqfa).
English: Tasmar tolcapone
Maltese: Tasmar tolkapon
English: The European Commission granted a marketing authorisation valid throughout the European Union for Tasmar on 27 August 1997.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Tasmar valida fl-Unjoni Ewropea kollha fis-27 ta' Awwissu 1997.
English: Tolcapone blocks an enzyme that is involved in the breakdown of levodopa in the body called catecholO-methyl transferase (COMT).
Maltese: It-tolkapon timblokka l-enzima li hija involuta fit-tkissir tal-levodopa fil-ġisem imsejħa katekol-O-metil transferażi (COMT - catechol-O-methyl transferase).
English: The CHMP decided that Tasmar's benefits are greater than its risks in combination with levodopa/benserazide or levodopa/carbidopa for use in patients with levodopa-responsive idiopathic Parkinson's disease and motor fluctuations, who failed to respond to or are intolerant of other COMT inhibitors.
Maltese: Is-CHMP iddeċieda li l-benefiċċji ta' Tasmar huma ikbar mir-riskji tiegħu f'kombinazzjoni ma' levodopa/benserazide jew levodopa/carbidopa għall-użu f'pazjenti li jkollhom il-marda ta' Parkinson idjopatika li tirrispondi għal-levodopa u fluttwazzjonijiet fiċ-ċaqliq, li ma jkunux irrispondew jew li jkunu intolleranti għall-inibituri oħra ta' COMT. Il-Kumitat irrakkomanda li Tasmar jingħata awtorizzazzjoni għat-tqegħid fis-suq.
English: Tasmar has also been studied in a ‘switch' study in 150 patients.
Maltese: Tasmar ġie studjat ukoll fi studju tal-qlib (switch study) f'150 pazjent.
English: The recommended dose is 100 mg three times a day.
Maltese: Id-doża rakkomandata hija ta' 100 mg tliet darbiet kuljum.
English: What is Tasmar?
Maltese: X'inhu Tasmar?
English: Tasmar is used together with other standard treatments for Parkinson's disease (either a combination of levodopa and benserazide or a combination of levodopa and carbidopa) when the patients have ‘fluctuations' towards the end of the period between two doses of their standard combination.
Maltese: Tasmar jintuża flimkien ma' trattamenti oħra standard għall-marda ta' Parkinson (jew kombinazzjoni ta' levodopa u benserazide jew kombinazzjoni ta' levodopa u carbidopa) meta l-pazjenti jkollhom ‘fluttwazzjonijiet' lejn tmiem il-perjodu bejn iż-żewġ dożi tal-kombinazzjoni standard tagħhom.
English: Why has Tasmar been approved?
Maltese: Għaliex ġie approvat Tasmar?
English: Tasmar is always given with levodopa and benserazide or with levodopa and carbidopa.
Maltese: Tasmar jingħata dejjem ma' levodopa u benserazide jew ma' levodopa u carbidopa.
English: What is the risk associated with Tasmar?
Maltese: Għal xiex jintuża Tasmar?
English: All of the studies compared Tasmar with placebo (a dummy treatment) when they were added to the patient's existing medication (levodopa and either carbidopa or benserazide).
Maltese: L-istudji kollha qabblu Tasmar ma' plaċebo (trattament finta) meta żdiedu mattrattament eżistenti tal-pazjent (levodopa u carbidopa jew benserazide).
English: How has Tasmar been studied?
Maltese: Kif ġie studjat Tasmar?
English: A risk management plan has been developed to ensure that Tasmar is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Tasmar jintuża bl-aktar mod sigur possibbli.
English: • signs of liver disease or increased liver enzymes;
Maltese: • sinjali ta' mard tal-fwied jew żieda fl-enzimi tal-fwied;
English: The active substance in Tasmar, tolcapone, works to restore the levels of dopamine in the parts of the brain that control movement and coordination.
Maltese: Is-sustanza attiva f'Tasmar, it-tolkapon, taħdem billi ġġib lura l-livelli ta' dopamina fil-partijiet tal-moħħ li jikkontrollaw il-moviment u l-koordinazzjoni.
English: Tasmar must also not be used in patients who are being treated with medicines known as nonselective monoamine oxidase (MAO) inhibitors.
Maltese: Tasmar lanqas m'għandu jintuża f'pazjenti li jkunu qed jiġu ttrattati b'mediċini magħrufa bħala inibituri mhux selettivi tal-monoamino ossidażi (MAO).
English: These patients were already receiving a combination of levodopa and entacapone (another medicine that blocks COMT).
Maltese: Dawn il-pazjenti kienu diġà qegħdin jirċievu kombinazzjoni ta' levodopa u entacapone (mediċina oħra li timblokka COMT).
English: Tasmar is used to treat patients with Parkinson's disease.
Maltese: Tasmar jintuża fit-trattament ta' pazjenti li jbatu mill-marda ta' Parkinson.
English: Parkinson's disease is a progressive brain disorder that causes shaking, slow movement and muscle stiffness.
Maltese: Il-marda ta' Parkinson hija disturb progressiv tal-moħħ li jikkawża rogħda, dewmien fil-movimenti u ebusija tal-muskoli.
English: Tasmar can cause liver injury, which can be fatal in rare cases.
Maltese: Tasmar jista' jikkawża ħsara fil-fwied, li tista' tkun fatali f'każijiet rari.
English: Physicians and patients should be made aware that there is an ad hoc advisory service available to provide information on leflunomide plasma level laboratory testing
Maltese: L-ispeċjalisti u l-pazjenti għandhom jiġu mgħarrfa li hemm disponibbli servizz ta' konsulenza ad hoc li jagħti informazzjoni dwar littestjar fil-laboratorju tal-livell ta' leflunomide fil-plażma.
English: • The Summary of Product Characteristics • Physician Leaflet
Maltese: • Is-Sommarju tal-Karaterristiċi tal-Prodott • Fuljett ta' Tagħrif għall-Ispeċjalista
English: • The identified risk of synergistic hepato- or haematotoxicity associated with combination therapy with another Disease-Modifying Antirheumatic Drug (e.g. methotrexate)
Maltese: • Ir-riskju magħruf li jekk tittieħed fl-istess ħin ma' mediċina oħra Antirewmatika li Timmodifika l-Kura (eż.methotrexate), l-epato jew l-ematotossiċità assoċjata ma' din itterapija kkombinata hija sinerġistika.
English: The Member States shall ensure that the Marketing Authorisation Holder (MAH) will provide physicians who are expected to prescribe/use Leflunomide medac with a physician educational pack containing the following:
Maltese: L-Istati Membri għandhom jiżguraw li d-Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq (MAH) ser jipprovdi lit-tobba li huma mistennija li jippreskrivu/jużaw Leflunomide medac b'pakkett edukattiv għattabib li jkun fih dan li ġej:
English: The information provided in the Physician Leaflet should provide information on dose reduction, discontinuation and wash out procedures.
Maltese: Linformazzjoni mogħtija fil-Fuljett ta' Tagħrif għall-Ispeċjalista għandha tagħti informazzjoni dwar it-tnaqqis fid-doża, it-twaqqif tal-kura u proċeduri ta' “wash-out”.
English: • That there is a risk of severe liver injury and so regular measurement of ALT (SGPT) levels to monitor liver function is important.
Maltese: • Li hemm riskju ta' ħsara serja fil-fwied u għalhekk huwa importanti li b'mod regolari jiġu aċċertati l-livelli tal-ALT (SGPT) sabiex il-funzjoni tal-fwied jinżamm taħt monitoraġġ.
English: EU/2/11/137/001 EU/2/11/137/002 EU/2/11/137/003 EU/2/11/137/004 EU/2/11/137/005 EU/2/11/137/006 EU/2/11/137/007 EU/2/11/137/008 EU/2/11/137/009 EU/2/11/137/010 EU/2/11/137/011 EU/2/11/137/012 EU/2/11/137/013 EU/2/11/137/014 EU/2/11/137/015
Maltese: EU/2/11/137/005 EU/2/11/137/006 EU/2/11/137/007 EU/2/11/137/008 EU/2/11/137/009 EU/2/11/137/010 EU/2/11/137/011 EU/2/11/137/012 EU/2/11/137/013 EU/2/11/137/014
English: Sand flies
Maltese: Sand fly
English: ATCvet code: QP53AC54.
Maltese: QP53AC54
English: See section 6.6
Maltese: Ara sezzjoni 6.6
English: 5831 AN Boxmeer The Netherlands
Maltese: 5831 AN Boxmeer L-Olanda
English: Date of first authorisation: 09/01/2012.
Maltese: DATA TAL-EWWEL AWTORIZZAZZJONI / TIĠDID TAL-AWTORIZZAZZJONI Data tal-ewwel awtorizzazzjoni: 09/01/2012
English: Recovery occurs normally within 24-36 hours after treatment.
Maltese: Rkupru normalment iseħħ fi żmien 24-36 siegħa wara t-trattament.
English: Propyl gallate (E310) Propylene glycol monomethyl ether (Dowanol PM)
Maltese: Propylene glycol monomethyl ether (Dowanol PM) 6
English: Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer The Netherlands
Maltese: Intervet International BV Wim de Körverstraat 35 5831 AN Boxmeer L-Olanda
English: PHARMACEUTICAL PARTICULARS 6.1 List of excipients
Maltese: 6.1 Lista ta' ingredjenti
English: 1 pipette 4 pipettes 6 pipettes
Maltese: Pipetta waħda Erba' pipetti Sitt pipetti
English: Intervet Productions SA Rue de Lyons 27460 Igoville France
Maltese: Rue de Lyons 27460
English: 0.5 Minimum of 15 Minimum of 48
Maltese: Minimu ta' 15 Minimu ta' 48
English: Indoxacarb is an ectoparasiticide belonging to the oxadiazine chemical family.
Maltese: Indoxacarb huwa ektoparasitiċida tal-familja kimika tal-oxadiazine.
English: Spot-on solution
Maltese: Soluzzjoni spot-on
English: Marketing authorisation holder: Intervet International BV Wim de Körverstraat 35
Maltese: Intervet International BV Wim de Körverstraat 35
English: 5.1 - 10 Small dogs
Maltese: 5.1 - 10 Klieb żgħar
English: VIRBAC DE PORTUGAL, LABORATÓRIOS LDA, R.do Centro Empresarial, Ed13-Piso 1- Esc.3, Quinta da Beloura, PT-2710-693 Sintra, Tel: + 351 219 245 020
Maltese: VIRBAC DE PORTUGAL, LABORATÓRIOS LDA, R.do Centro Empresarial, Ed13-Piso 1- Esc.3, Quinta da Beloura, PT-2710-693 Sintra,
English: ж.к.Люлин 10, бл.145, ergon-m@mbox.contact.bg
Maltese: Ергон-Миланова ЕООД, Р България, гр.София, ж.к.Люлин 10, бл.145, ergon-m@mbox.contact.bg
English: Method of administration:
Maltese: Metodu ta' applikazzjoni:
English: The pipette consists of a blister film (polypropylene/cyclic-olefin- copolymer/polypropylene) and a foil lidstock (aluminium/polypropylene co-extruded) sealed into aluminium child-resistant sachet.
Maltese: Il-pipetta tikkonsisti f'qoxra (polypropylene/cyclic-olefin-copolymer/polypropylene) u tapp tal-folja (aluminium/polypropylene co-extruded) issiġillati fi qratas tal-aluminju.
English: Dogs.
Maltese: Biss.
English: Volume (ml)
Maltese: (ml)
English: 5.1 Pharmacodynamic properties
Maltese: 5.1 Kwalitajiet Farmakodinamiċi
English: One ml contains 150 mg indoxacarb and 480 mg permethrin.
Maltese: Ml wieħed fih 150 mg indoxacarb u 480 mg permethrin.
English: Signs related to the nervous system can be treated with e.g. atropine (salivation) and diazepam (muscle tremors/fasciculation/cramp).
Maltese: Sinjali relatati mas-sistema nervuża jistgħu jiġu ttrattati b`eż. atropina (salivazzjoni) u diazepam (rodgħa talmuskoli/fasciculation/bugħawwieġ).
English: - BP 27, FR-06517 Carros, service-conso@virbac.fr
Maltese: VIRBAC France, 13ème rue - L.I.D. - BP 27, FR-06517 Carros, service-conso@virbac.fr
English: VIRBAC HELLAS A.E.,
Maltese: VIRBAC HELLAS A.E., 13ο χλμ.
English: The product has persistent acaricidal efficacy for up to 5 weeks against Ixodes ricinus and up to 3 weeks against Rhipicephalus sanguineus.
Maltese: Ixodes ricinus u sa 3 ġimgħat kontra Rhipicephalus sanguineus.
English: One pipette delivers:
Maltese: Sabiex tevita reazzjonijiet mhux mixtieqa:
English: PACKAGE LEAFLET: Activyl Tick Plus spot-on solution for dogs
Maltese: FIL-PAKKETT: Activyl Tick Plus soluzzjoni spot-on għal klieb
English: VIRBAC SRL, Via Ettore Bugatti, 15, IT-20142 Milano, Tel: + 39 02 40 92 47 1
Maltese: VIRBAC SRL, Via Ettore Bugatti, 15, IT-20142 Milano,
English: Ensure that the dosage (pipette) corresponds to the weight of the treated dog (see section 4.9).
Maltese: Assigura li d-doża (pipetta) tikkorrispondi mal-piż tal-kelb trattat (ara sezzjoni 4.9)
English: Permethrin belongs to the Type I class of pyrethroids, which are acaricides and insecticides with repellent activity.
Maltese: Permethrin jiġi mill-klassi tal-pyrethroids tat-Tip I, li huma akaraċidi u insettiċidi b'attività repellenti.
English: Pyrethroids affect the voltage-gated sodium channels in vertebrates and non- vertebrates.
Maltese: Pyrethroids jaffettwaw il-kanali tas-sodju dipendenti fuq il-vultaġġ fil-vertebrati u fin-non vertebrati.
English: Treatment of flea infestations (Ctenocephalides felis); the product has persistent insecticidal efficacy for up to 4 weeks against Ctenocephalides felis.
Maltese: Trattament ta' infestazzjonijiet bil-briegħed (Ctenocephalides felis); il-prodott għandu effett insettiċidali persistenti sa' 4 ġimgħat kontra Ctenocephalides felis.